NJ-METLIFE
MetLife Investment Management (MIM) , the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that MetLife Investment Management Europe Limited (“MIM Europe”) has been authorized by the Central Bank of Ireland (“CBI”) to manage and market AIFs and UCITS, two vehicles through which European investors can best access MIM’s investment capabilities. Additionally, the license allows MIM Europe to offer and manage MIM’s full range of investment strategies across the European Economic Area (“EEA”).
Headquartered in Dublin, Ireland, MIM Europe will serve as the hub for MIM’s business in the EEA. Today, MIM has a significant presence in Europe across a range of client segments and countries. The authorization will enable broader access to the EEA market.
“This affirms our commitment to expand our offerings in Europe and will allow us to take an increasingly local approach to serving the market,” said Matthew Mosca, global head of the Institutional Client Group at MIM. “We have already seen demonstrated demand for our core investment products in Europe, and the CBI license will allow MIM to further leverage both our U.S. and Europe-based product and management capabilities in ways directly suited to European institutional investors.”
“The authorization of MIM Europe is a clear demonstration of the central role we expect Europe to continue to play in MIM’s international expansion, and of our desire to deliver our full breadth of investment capability to European investors,” said Nigel Murdoch, managing director and head of EMEA for MIM’s Institutional Client Group. “We look forward to collaborating with investors across Europe on the delivery of strong, long-term, sustainable investment returns.”
About MetLife Investment Management
MetLife Investment Management
, the institutional asset management business of MetLife, Inc. (NYSE: MET), is a global public fixed income, private capital and real estate investment manager providing tailored investment solutions to institutional investors worldwide. MetLife Investment Management provides public and private pension plans, insurance companies, endowments, funds and other institutional clients with a range of bespoke investment and financing solutions that seek to meet a range of long-term investment objectives and risk-adjusted returns over time. MetLife Investment Management has over 150 years of investment experience and, as of December 31, 2021, had $669.0 billion in total assets under management.
1
About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com
.
Endnotes
1
Total AUM is comprised of all MetLife general account and separate account assets and unaffiliated/third party assets, at estimated fair value, managed by MIM.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005633/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 14:03:00 CET | Press release
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20
Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 14:00:00 CET | Press release
Strategic collaboration to bring innovative residential solutions designed to reduce emissions and enable sustainable home heating Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press release
Visa Consulting & Analytics combines advanced payments strategy and expert crypto knowledge to help clients innovate and grow with stablecoins technology Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
